Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Radi Medical, GE combine to integrate haemodynamic tech

This article was originally published in Clinica

Executive Summary

Swedish medtech firm Radi Medical Systems is set to integrate its wireless PressureWire Aeris and fractional flow reserve (FFR) technology into GE Healthcare’s Mac-Lab IT haemodynamic recording system. The two firms have partnered in a development, marketing and sales agreement that will, according to Uppsala-based Radi Medical, bring "faster and easier" wireless, FFR assessment into cath lab workflow. The deal will see existing Mac-Lab customers be provided with an upgrade for Radi Medical’s additional applications. Financial terms of the deal were not disclosed. FFR is an index used to determine the severity of ischaemia in heart vessels. Traditionally, the recording of FFR measurements required the set-up of additional instrumentation, screens and controls.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT042400

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel